t-cell

Documents about t-cell

• Regulatory T cell therapies: biological foundations, engineering strategies, and clinical translation#257538HAL (France)
• A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies#314331ClinicalTrials.gov
• CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)#268013ClinicalTrials.gov
• Integrating T cell signaling and metabolism to enhance T cell engager responses in solid tumors.#434009NCBI PubMed Central
• A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas#811006ClinicalTrials.gov
• Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma#841375ClinicalTrials.gov
• Production de lymphocytes T à Récepteur d'Antigène Chimérique pour améliorer l’immunothérapie anti-tumorale#213132HAL (France)
• BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma#831996ClinicalTrials.gov
• Study on the Effect of Oral Diammonium Glycyrrhizinate in Attenuating Toxicity and Enhancing Efficacy of CAR-T Cell Therapy#844493ClinicalTrials.gov
• Invasive fungal infections after CD19 chimeric antigen receptor T-cell therapy for B-cell lymphoma: a Lymphoma study association study from the DESCAR-T (Dispositif d’Enregistrement et Suivi des patients traités par CAR-T cells) registry#239043HAL (France)
• Management Practices of CAR T-cell-Related Inflammatory Toxicities: A Survey of Pediatric CAR T-cell Providers.#232384NCBI PubMed Central
• Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion#417535ClinicalTrials.gov
• Tislelizumab Combined with Mitoxantrone Hydrochloride Liposome in Extranodal Natural Killer/T Cell Lymphoma#640561ClinicalTrials.gov
• PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma#810554ClinicalTrials.gov
• CD19/22 Bi-specific CAR-T Cell Therapy#811795ClinicalTrials.gov
• Functional Exhaustion of T Cells in COVID19 Patients#843322ClinicalTrials.gov
• Immune synapse molecules knockout in induced pluripotent stem cells enables broad NK cell resistance in T cell progeny#308577Kyoto University Research Information Repository
• Immune synapse molecules knockout in induced pluripotent stem cells enables broad NK cell resistance in T cell progeny#308582Kyoto University Research Information Repository
• Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma#846032ClinicalTrials.gov
• Vaccine Responsiveness After CAR-T Cell Therapy#201619ClinicalTrials.gov
• The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma#174875ClinicalTrials.gov
• Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.#353293ClinicalTrials.gov
• Alemtuzumab and Pentostatin In T-cell Neoplasms#810935ClinicalTrials.gov
• A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy#181780ClinicalTrials.gov
• A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL#827897ClinicalTrials.gov
• INfections in Patients Treated With CAR-T#839746ClinicalTrials.gov
• Editorial: Deciphering the T cell response in SARS-CoV-2 infection#250590IRIS
• Genetic Engineering of Notch1 Regulatory Elements to Improve CD19 CAR T-cell Proliferation and Persistence#273814Harvard DASH
• Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies#442106ClinicalTrials.gov
• Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell#804696ClinicalTrials.gov
• A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)#143561ClinicalTrials.gov
• Improvement of skin manifestations of refractory connective tissue diseases by T-cell engager treatment#303081ARPHA OAI-PMH Endpoint
• Valganciclovir to Reduce T Cell Activation in HIV Infection#829455ClinicalTrials.gov
• Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma#338805OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• Clonal expansion of CAR-T cells harboring lentivector integration in the PLAAT4 gene following anti-CD19 CAR T-cell therapy in a context of cutaneous T-cell lymphoma#342177HAL (France)
• Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma#674900ClinicalTrials.gov
• BAG2 Condensates Couple Proteostasis to CD8+T Cell Surveillance#226023bioRxiv / medRxiv
• Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant#830441ClinicalTrials.gov
• LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies#846631ClinicalTrials.gov
• How the wild things are: comparative T cell phenotyping and memory T cell identification in wild boar and domestic pigs.#338542NCBI PubMed Central
• Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)#837712ClinicalTrials.gov
• Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas#839139ClinicalTrials.gov
• CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.#140998ClinicalTrials.gov
• Bioinformatic identification of CD8+ T cell activation mediated by key genes in fecal microbiota transplantation for irritable bowel syndrome#285419PLOS
• Deep exploration of the TCR CDR3β repertoire specific for viral CD4 T-cell epitopes inside the circulating T-cell repertoire#417985HAL (France)
• Genetic disruption of Pdcd-1 upstream enhancer boosts T cell function and antitumor responses#189772Kyoto University Research Information Repository
• Genetic disruption of Pdcd-1 upstream enhancer boosts T cell function and antitumor responses#189811Kyoto University Research Information Repository
• VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)#804878ClinicalTrials.gov
• Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma#807863ClinicalTrials.gov
• A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma#830678ClinicalTrials.gov